Spotlight session: Decentralising cell therapy delivery - building the supply chain for wider access

As regulatory frameworks evolve, including the FDA lifting REMS requirements for cell therapies, opportunities arise to broaden patient access. This session explores how manufacturers and supply chain stakeholders can overcome infrastructure challenges, equip local hospitals, and ensure traceability and timely delivery in decentralized networks. 

Key takeaways:  

• Assess the impact of regulatory changes on decentralized cell therapy access 

• Identify infrastructure requirements for hospitals, including storage and cold chain management 

• Maintain product integrity and traceability across multiple treatment sites 

• Optimize logistics and delivery workflows to support timely patient treatment 

• Explore strategies to scale supply chains while maintaining quality and compliance